FDA expected to add Guillain-Barre syndrome warning to J&J Covid shot



FDA is preparing to add a warning to Johnson & Johnson's Covid-19 vaccine after receiving preliminary reports of patients developing the rare neurological condition Guillain-Barré syndrome after receiving the shot, a senior CDC official confirmed to POLITICO.

About 100 suspected cases of GBS — among the 12.8 million people who have gotten the J&J shot — have been identified in the federal government's database for adverse side effects after vaccination, the official said.

While those reports are “rare,” the official said, they “do likely indicate a small possible risk of this side effect following this vaccine.” But the benefits of the J&J shot outweigh the risks of contracting the virus, the CDC official said. Nearly all hospitalizations and deaths linked to Covid in the U.S. are occurring among unvaccinated people.

Spokespeople for FDA and J&J did not immediately respond to requests for comment.

The Washington Post first reported FDA's plans.

The significance: GBS is a rare condition in which the body's immune system attacks nerve cells. About 3,000 to 6,000 people develop the syndrome every year in the U.S.; most fully recover, though paralysis can occur in the most serious cases.

GBS has been linked as a rare side effect to other vaccines, including a shot developed to fight the 1976 swine flu. Most adverse side effects tied to vaccines are identified within two months of inoculation.

Most of the instances identified in the federal database were reported approximately two weeks after vaccination and were predominantly seen in males ages 50 and older, the senior CDC official said.

“Available data do not show a similar pattern with” the Pfizer and Moderna vaccines, the official said, which are made using a different vaccine technology. Those vaccines have been linked to rare cases of myocarditis, an inflammatory condition of the heart, largely among males younger than 30.

What's next: The CDC's vaccine advisory committee will discuss the issue at an “upcoming” meeting, the official said.

View original post